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Background: D6 regulates resolution of inflammatory responses. Its mode of action has not been molecularly defined.
Results:Microarray analysis of inflamed D6-deficient mouse skin identifies dysregulated type I interferon responses as under-
pinning exaggerated inflammatory responses in D6-deficient mice.
Conclusion: D6 is important for regulating type I interferon-based responses in inflammation.
Significance: The study provides novel insights into roles for D6 in the resolution of inflammatory responses.
The inflammatory response is normally limited by mecha-
nisms regulating its resolution. In the absence of resolution,
inflammatory pathologies can emerge, resulting in substantial
morbidity andmortality.We have been studying the D6 chemo-
kine scavenging receptor, which played an indispensable role in
the resolution phase of inflammatory responses and does so by
facilitating removal of inflammatory CC chemokines. In D6-de-
ficient mice, otherwise innocuous cutaneous inflammatory
stimuli induce a grossly exaggerated inflammatory response
that bears many similarities to human psoriasis. In the present
study, we have used transcriptomic approaches to define the
molecular make up of this response. The data presented high-
light potential roles for a number of cytokines in initiating and
maintaining the psoriasis-like pathology.Most compellingly,we
provide data indicating a key role for the type I interferon path-
way in the emergence of this pathology. Neutralizing antibodies
to type I interferons are able to ameliorate the psoriasis-like
pathology, confirming a role in its development. Comparison of
transcriptional data generated from this mouse model with
equivalent data obtained from human psoriasis further
demonstrates the strong similarities between the experimen-
tal and clinical systems. As such, the transcriptional data
obtained in this preclinical model provide insights into the
cytokine network active in exaggerated inflammatory responses
and offer an excellent tool to evaluate the efficacy of com-
pounds designed to therapeutically interfere with inflamma-
tory processes.
Inflammatory responses are characterized by leukocyte
migration to the inflamed site, a process ultimately dependent
on chemokines and their receptors (1, 2). Chemokines are
defined on the basis of the presence of a characteristic cysteine
motif in their mature sequences, which is used to divide the
chemokine family into four subfamilies. The two largest subdi-
visions comprise the CC and CXC subfamilies, whereas the XC
and CX3C subfamilies are grouped in substantially smaller
clusters.Mice and humans have45 chemokines (3), which are
involved, in sometimes extremely complex ways, in regulating
in vivo leukocyte migration. Given the complexity of chemo-
kine biology, it is common to simplify things by defining
chemokines as being either homeostatic or inflammatory,
according to the in vivo contexts in which they function (2, 4).
Thus homeostatic chemokines regulate basal leukocyte traf-
ficking to peripheral tissues and lymph nodes, whereas inflam-
matory chemokines are specifically involved in the attraction of
inflammatory leukocytes to damaged or infected body sites. In
the context of inflammatory responses, numerous chemokines are
expressed simultaneously, and their overall amount and assort-
ment orchestrate the migration of a variety of inflammatory leu-
kocytes to the inflamed site. Effective resolution of inflammatory
responses is dependent on appropriate and timely clearance of
inflammatory chemokines from inflamed sites. In the absence of
such clearance, the inflammatory response persists, and chronic
pathologies evolve.
The chemokine scavenging receptor D6 (5, 6) is a prototypic
member of the atypical chemokine receptor family. This family
is defined on the basis of the inability of its members to mount
classical receptor signaling responses following ligand binding
(7–9). D6 is a promiscuous receptor with a binding selectivity
for inflammatory CC chemokines (5, 6, 10, 11). D6 is an
extremely efficient internalizer and degrader of inflammatory
CC chemokines (12–15) and in this way contributes to the res-
olution of the inflammatory response. Mice deficient in D6 dis-
play a range of inabilities to resolve inflammatory responses in
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the tissues in which D6 is normally expressed. Thus D6-defi-
cient mice display exaggerated cutaneous (16, 17), pulmonary
(18), and gut (according to the specific model used (19, 20))
inflammatory responses, and in the context of the skin and gut,
D6-deficient mice display enhanced tumorigenic programs in
murine models of inflammation-dependent cancer develop-
ment (20, 21). The major site of D6 expression is lymphatic
endothelium (22), and we have hypothesized a role for lym-
phatic endothelial cell D6 in ensuring efficient drainage, and
thus, removal of inflammatory chemokines and cytokines from
inflamed sites (23, 24). In this way, we have suggested that the
major role for D6 is to ensure the openness of the lymphatic
drainage channels and that the exaggerated inflammatory
response seen in D6-deficient mice relates to the inability of
these mice to efficiently remove inflammatory cytokines and
chemokines from inflamed sites. In keeping with its experi-
mentally demonstrated role as a regulator of inflammatory
responses, D6 has been shown to be broadly expressed in a
range of inflammatory pathologies, suggesting a role in disease
pathogenesis (25–28). Interestingly, D6 is expressed in a variety
of cell types in inflammatory pathologies, including keratino-
cytes and peripheral blood leukocytes. It is therefore clear that
D6 contributes to the resolution of the inflammatory response
in a range of ways likely to involve both lymphatic endothelial
cells as well as other cell types.
We have been particularly interested in examining the func-
tion of D6 in cutaneous inflammatory responses. Previously we
have published that althoughWTmice display amild and tran-
sient inflammatory response to phorbol ester (TPA)3 applica-
tion, D6-deficient mice are unable to efficiently resolve this
response (16) and develop a pathology that is similar, in numer-
ous ways, to human psoriasis (26). The pathology develops in a
characteristic temporal fashion, thus allowing the cellular and
molecular basis to be defined. The purpose of the present study
was to define the molecular signature of the cutaneous inflam-
matory pathology induced in D6-deficient mice with a view to
understanding the precise roles for D6 in regulating inflamma-
tion. Here we report transcriptional evidence indicating that
challenged D6-deficient mice mount a type I interferon-based
response that is essential for the development of the cutaneous
inflammatory pathology. These data further elucidate the
mechanism of action of D6 and suggest a close association
between D6 function and the suppression of type I interferon-
dependent inflammatory responses.
EXPERIMENTAL PROCEDURES
Irritation of the Skin with the Phorbol Ester TPA—Dorsal skin
of female 129-C57BL/6mice (16) (8–12 weeks old) was shaved,
and three applications of TPA (Sigma P1585, 50 M, 150
l/mouse) or acetone (150 l/mouse) were applied to the skin
at 24-h intervals. The cutaneous inflammation was left to
develop for 1, 2, 4, and 6 days after the three TPA applications.
Dorsal skinwas removed frommice at each of these time points
and stored in RNAlater (Invitrogen AM7020) for 24 h at 4 °C
(for RNA purification) or fixed in formalin overnight at 4 °C for
subsequent histological analysis.
RNA Extraction—Skin was removed from RNAlater and
stored at 80 °C until processing. To extract RNA, back skin
was ground into a powder in liquid N2, and RNAwas extracted
using TRIzol and the PureLink RNA kit (Ambion 12183018A)
according to the manufacturer’s instructions. RNA concentra-
tions were quantified using the Nanodrop (Thermo Scientific)
and stored at80 °C.
Histology—Formalin-fixed skin samples were transferred to the
tissueprocessor (ThermoScientific) andprogressivelydehydrated
over 20 h to xylene through successive concentrations of ethanol.
Skinswereembedded inparaffinwax, and8-msectionswerecut,
mounted onto Superfrost Slides (Fisher 12-550-15), and stored at
4 °C until required.
Hematoxylin and Eosin Staining—Paraffin-embedded skin
sectionswere rehydratedwithwater and stainedwith hematox-
ylin and eosin according to standard procedures. Briefly, slides
were stained with hematoxylin (2min), dipped in 1% acid/alco-
hol twice, rinsed in water, immersed in Scotts Tap water sub-
stitute (30 s), rinsed in water, and stained with eosin (2 min).
Slides were dehydrated to xylene, mounted in dibutyl phthalate
xylene, and visualized on a light microscope (Carl Zeiss).
TCell Staining—Paraffin-embedded skin sectionswere rehy-
dratedwith water, blockedwith 20% horse serum in TBS-0.01%
Tween 20 (TBST) for 30 min at room temperature, and incu-
bated with a rabbit anti-human CD3 antibody (Dako) for 1 h at
room temperature in TBST. Excess antibody was removed by
washing twice in TBST, and staining was detected using the
DakoEnvision kit according to themanufacturer’s instructions.
The slides were dehydrated to xylene, mounted in DPX, and
visualized on a light microscope (Carl Zeiss).
Microarray Analysis—Microarrays were performed using
Affymetrix Mouse Genome 430 2.0 Exon Expression Arrays
and subsequently analyzed using GeneSpring GX (Agilent).
Three WT and three D6-deficient mice were used per time
point over the four time points, and three acetone-treated con-
trols were used for both D6-deficient and wild type mice.
Microarray data were normalized using robustmultiarray anal-
ysis and base-line-transformed to the median of the control
samples (acetone-treated D6-deficient or WT mice) to allow
visualization of both lowly and highly expressed genes. TPA-
treated WT or D6-deficient mice were compared with their
respective controls robust multiarray analysis normalization
involved three steps: background correction (to remove noise),
quantile normalization (to adjust for “chip to chip” variation),
and summarization (to transform the data onto a log2 scale and
remove outliers). To base-line transform the data, the median
of the control samples, the log2 normalized intensity value for
each gene in the TPA-treated samples was subtracted from the
median normalized intensity value of the equivalent gene from
the respective acetone-treated control sample (D6-deficient or
WT mice). To remove noise and lowly expressed genes, the
lower 20% of genes expressed were removed. Principal compo-
nent analysis was performed to determine whether particular
chips were outliers. Lists of significantly expressed genes were
analyzed using gene ontology analysis to subsequently identify
significantly changed families of genes. Hierarchical clustering
within entities was also performed to identify gene expression
patterns within the data. Ingenuity pathway analysis was used3 The abbreviation used is: TPA, 12-O-tetradecanoylphorbol-13-acetate.
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to identify potential differentially expressed pathways altered in
D6-deficient mice compared with WTmice at each time point
within gene lists identified using hierachical clustering. The
data discussed in this publication are MIAME-compliant and
have been entered into the NCBI Gene Expression Omnibus
(accessible online under accession number GSE46889).
Real Time PCR—RNA (1 g) was reverse transcribed to
cDNA using the Quantitect reverse transcription kit (Qiagen
205311) according to the manufacturer’s instructions. Gene
expression was measured by absolute quantification compared
with-actin. DNA standards weremade by cloning into TOPO
TA cloning vector (Invitrogen 450641) using the primer
sequences in Table 1. cDNA was diluted 1:5 and mixed with
PerfeCTa SYBR green FastMix (Quanta Biosciences 95072-
250) and quantitative PCR primers (Table 1). The plate was run
on an ABI 7900HT fast real time PCR System (ABI) under the
conditions recommended for SYBR green by the manufacturer
(Quanta Biosciences).
Neutralizing IFN- and IFN- in TPA-treated Mice—Neu-
tralizing antibodies against IL-6 (rat anti-mouse), IL-20 (rat
anti-mouse), IFN- (rabbit anti-mouse), and IFN- (rabbit
anti-mouse), as well as isoptype and sera controls, were pur-
chased from R&D Systems. Antibodies were injected intrave-
nously into WT and D6-deficient mice (8–12 weeks old), 3 h
before the first application of TPA (Sigma P1585, 50 M, 150
l/mouse). A further application of TPAwas applied as normal
24 h later. The following day, the same amount of antibody or
isotype control was injected intravenously, 3 h before the final
application of TPA. Mice therefore received two doses of anti-
body or isotype control and three applications of TPA. Pathol-
ogy was left to develop for 4 days, after which dorsal skin was
taken for histology and quantitative PCR.
Statistical Analysis—The data were analyzed using unpaired
t tests comparingD6-deficient withWTmice. p 0.05 denotes
significance.
RESULTS
D6-deficientMiceDisplayaTemporallyReproduciblePatternof
Development of Exaggerated Cutaneous Inflammation—We have
previously published that D6-deficient mice display a markedly
exaggerated response to mild cutaneous inflammatory stim-
uli (16). Because this represents a uniquely tractable model of
impaired resolution of chemokine-driven inflammatory
responses, we initiated a study aimed at investigating the tran-
scriptomic basis for the cutaneous inflammatory pathology in
D6-deficient mice with the hope that this may shed novel light
on the molecular mechanisms of impaired resolution of cuta-
neous inflammation. Fundamental to this study was the obser-
vation that D6-deficient mice develop the inflammatory skin
pathology in a defined temporal manner. As shown in Fig. 1A,
uninflamed WT and D6-deficient mouse skin sections (day 0)
are histologically indistinguishable. However, although WT
mice develop a very mild and transient inflammatory response
peaking at day 2 after TPA treatment, D6-deficient mice
develop a much more profound inflammatory response, which
is evident as early as day 1 after TPA treatment and which has
not completely resolved even by day 6. Epidermal thickness,
used as a quantitative surrogate measure of the extent of
inflammation (Fig. 1B), confirmed the enhanced inflammatory
response in D6-deficient mice at day 4 and also revealed that
this is significantly greater than that seen with WT mice at the
same time point.We have previously reported that a character-
istic of the cutaneous inflammatory response developing in
D6-deficient mice is the presence of T cells within the inflamed
epidermis. As shown in Fig. 1C, and as enumerated in Fig. 1D,
whereasWTmice show only a low level of T cell accumulation
in the epidermis at day 4, D6-deficient mice show a highly sig-
nificantly increased presence of such cells. This identical pat-
tern of development of inflammation was seen in all mice used
in this study, thus confirming the temporal reproducibility of
the response.
Inflamed Skin of D6/Mice Exhibit a Distinct Gene Expres-
sion Pattern—To investigate the transcriptional program
underpinning the gross inflammatory response seen in D6-de-
ficient mice, we harvested skin from TPA-treated D6-deficient
and WT mice at the indicated time points, isolated RNA, and
determined the differentially expressed genes using a microar-
ray approach. Bioinformatic analysis of the data generated
demonstrated that thereweremajor differences in gene expres-
sion patterns between inflamed skin fromD6-deficient andWT
mice and that this was temporally regulated (Table 2). At base
line, 48 genes were differentially regulated between D6-defi-
cient and WT mice (13 up-regulated and 35 down-regulated;
detailed in supplemental Table S1), although pathway analysis
indicated that these genes represented no common biological
process. These basal differenceswere taken into account in sub-
sequent analyses by normalizing transcriptomic data from later
time points for D6-deficient or WT TPA-treated samples to
their respective untreated controls. In D6-deficient mice, over
time, a total of 90 entities (30 up-regulated and 60 down-regu-
lated) were altered at day 1 (supplemental Table S2), 406 (195
up-regulated and 211 down-regulated) were altered at day 2
(supplemental Table S3), 150 (49 up-regulated and 101 down-
regulated)were altered at day 4 (supplemental Table S4), and 41
(20 up-regulated and 21 down-regulated) were altered at day 6
(supplemental Table S5). Thus the major differences in gene
expression betweenD6-deficient andWTmice occurred at day
2, preceding the major differences in pathology, which were
apparent at day 4 (Fig. 1A).
TABLE 1
PCR primer sequences
Primer sequences were designed for measurement of gene copy number by quanti-
tative PCR. Standards with a known copy number were generated by cloning into
TOPO using the indicated primer sequences. The quantitative PCR was performed
using the quantitative PCR primers and SYBR green. The copy number of each gene
was measured using a standard curve generated using the cloned standards. Gene
transcription was normalized to -actin.
Gene Forward (5-3) Reverse (5-3)
Quantitative
PCR
Irf7 TGTTTGGAGACTGGCTATTGG ATCCCTACGACCGAAATGCT
Ifit2 GAAAAAGAAAGCCCTCACCAA GTTCCCCAAACTCCTGACAA
CXCL9 TTTCTCCCTCCCTCCCTTC TTTTCACCCTGTTGGCTCT
-Actin CGTTGACATCCGTAAAGACC CTGGAAGGTGGACAGTGAG
Standards
Irf7 TGTGACCCTCAACACCCTA GAGCCCAGCATTTTCTCTTG
Ifit2 CAGGAGAATGGAGGAGGTC CTGAAACAAGCCCAAGACAAG
CXCL9 CCTCCTTGCTTGCTTACCAC AACTCTGGCTCCCTTCC
-Actin GCTCTTTTCCAGCCTTCCTT GCTCAGTAACAGTCCGCCTA
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Gene Ontology Analysis Reveals Differential Expression of
Members of Specific Gene Families—We next used gene ontol-
ogy analysis to associate differentially expressed gene profiles
with individual functional families by registering those families
of genes that were significantly altered in D6-deficient, com-
pared withWT,mice at each time point. Note that this analysis
identifies gene families displaying significant alterations but
does not rely on directionality and thus incorporates both up-
and down-regulated genes in the analysis. We found that the
number of genes that significantly fell into a particular family at
day 1 was small, reflective of the relatively few genes (90 genes)
differentially expressed at this time point. The majority of the
genes differentially expressed at day 1 fell into families involv-
ing “DNA methylation” and “alkylation,” characteristic of skin
FIGURE1.D6KOmice showanexaggeratedcutaneous inflammatory response.The shaveddorsal skins ofD6-deficient orWTmicewere treatedwith three
applications of TPA (150 l, 50 M) or acetone (untreated mice), and the inflammatory pathology was left to develop for 1, 2, 4, and 6 days. A, histological
analysis (H&E staining) of thedevelopmentof theexaggeratedcutaneous inflammatorypathology inD6-deficient (D6KO) comparedwithwild typemiceat the
indicated time points after TPA treatment. Uninflamed skin (day 0) of acetone-treated wild type and D6 KOmice is also shown for comparison. B, assessment
of the extent of cutaneous inflammation by quantification of epidermal thickness at the peak of the inflammatory pathology (day 4 after TPA treatment). Each
point represents the mean of nine separate measurements. **, p 0.001. C, demonstration of the exaggerated T cell accumulation in inflamed D6 KOmouse
skins as revealedbyCD3stainingofday4 skins.D, quantitationof theT cell accumulation in resting (WTandD6KO) and inflamed (day4WTTPAandKOTPA)
WT and D6 KO skins. Each point represents the mean of nine separate measurements. *, p 0.05.
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turnover (Fig. 2A). However, the large number of genes dif-
ferentially expressed at day 2 (406 genes) were preferentially
associated with alternative gene families implicated in
inflammatory responses such as “immune response,” “defense
response,” “immune system process,” “inflammatory response,”
and “response to wounding” (Fig. 2B). These differences were
reflected in significant alterations in the temporal pattern and
intensity of chemokine and chemokine receptor expression in
the D6-deficient mice at this time point (supplemental Fig. S1,
A and B). Specifically, and in contrast to WT mice, numerous
inflammatory chemokines were overrepresented at day 2 in the
D6-deficient mice. There was also enhanced representation of
the inflammatory CC chemokine receptors CCR1, CCR2, and
CCR5 (but not CCR3), indicative of increased accumulation of
inflammatory cells bearing these receptors (supplemental Fig.
S2). Notably, there was a significant reduction in expression of
CCL20 as well as the CCR4 ligands CCL17 and CCL22 in
D6-deficient mice compared with WT mice at this time point,
indicating a potential shift away from atopic responses toward a
more straightforward inflammatory response (supplemental
Fig. S1B). In contrast to the major representation of inflamma-
tory gene families at day 2, we found, after 4 days, that themajor
families of genes altered were those implicated in “keratinocyte
differentiation,” “proliferation,” and “epidermal development”
(Fig. 2C),matchingwith the histology (Fig. 1A), which indicated
that the major differences in epidermal thickness were appar-
ent at this time point (Fig. 1, A and B). These transcriptional
alterations are reflected inmarked differences in the expression
of a broad range of genes involved in epidermal cell prolifera-
tion and cutaneous remodelling. Specifically, as shown in sup-
plemental Fig. S3, there were differences in expression of a
range of keratin genes indicative of the aberrant epidermal dif-
ferentiation apparent in the inflamed D6-deficient skins. Fur-
thermore, there was down-regulation of a large number of
members of the Lce1 class of late cornified envelope genes,
which encode proteins that have been strongly implicated as
being involved in the development of a range of cutaneous
inflammatory pathologies (29, 30), most notably psoriasis. Also
evident in supplemental Fig. S3 is the down-regulation of the
epidermal genes Involucrin (Ivl) and Fillagrin (Flg). Together,
these gene differences reflect the marked alterations in epider-
mal proliferation and differentiation in the D6-deficient mice.
At day 6, the differences in gene expression between D6-defi-
cient and wild type mice had largely been removed and again
were restricted to genes involved in basic cellular processes
(Fig. 2D).
Inflamed D6-deficient Mouse Skin Is Characterized by Altered
Expression of a Range of Key Inflammatory Cytokines—We next
examined the differential expression of a range of cytokines
involved in inflammatory responses and of known relevance to
cutaneous inflammatory disorders (31–33). As shown by the
profile plots in Fig. 3, a number of patterns was observed. First,
some inflammatory cytokines displayed identical levels of tran-
scriptional induction in inflamed WT and D6-deficient mouse
skins (Fig. 3A) including IL-1, IL-6, and TNF. However,
whereas the temporal expression patterns of IL-6 were the
same in WT and D6-deficient skins, IL-1 was induced earlier
in the inflammatory process in D6-deficient skin compared
with WT skins (p  0.01), and TNF displayed a similar, albeit
not significant, trend. IL-17A (p 0.01) and IL-22 (p 0.0001)
were overexpressed in the D6-deficient mouse skins compared
with WT skins, as was IL-15, but this difference did not reach
statistical significance (Fig. 3B). Finally, other cytokines dis-
played markedly reduced expression in D6-deficient skins (Fig.
3C), including IL-1 (p  0.0001) and IL-20 (p  0.01). Inter-
estingly, overexpression of IL-17A and IL-22 peaked at day 4,
which contrastswith the peak expression of these two cytokines
in WT mice at day 2, suggesting that their expression is main-
tained inappropriately in D6-deficient mice. We have previ-
TABLE 2
Number of differentially expressed genes at each time point
Number of differentially up- or down-regulated genes in inflamedD6-deficient skin
compared to inflamed wild type skin at each time point. Genes, referred to as
“entities,” differentially up- or down-regulated in D6-deficient skin compared to
wild type skin at 0, 1, 2, 4, or 6 days after TPA application are enumerated. At each
time point, entities significantly (p 0.05) up- or down-regulated (fold change,3)
were selected. The total number of entities identified to be significantly changed at
each time point is indicated.
Time Total entities Up-regulated Down-regulated
0 days 48 13 35
1 days 90 30 60
2 days 406 195 211
4 days 150 49 101
6 days 41 20 21
FIGURE 2.Gene ontology analysis of themajor families of genes display-
ingdifferential expression at the indicated timepoints.Gene families dis-
playing significantly altered expression (incorporating both up- and down-
regulated genes) in D6 KO skin compared with wild type skins (3-fold, p
0.05). Gene expression differences at each time point: day 1 (A), day 2 (B), day
4 (C), and day 6 (D) were grouped into gene families using gene ontology
analysis (Genespring). The number of geneswithin the list of significantly up-
or down-regulated genes at each time point that fell into a particular gene
family is indicated (Count in Group). Note the changes in the major altered
gene families over the time course, particularly at day 2.
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ously reported that the pathology that develops in the D6-defi-
cient mice can be blocked using antibodies, or other blocking
agents, for TNF, IL-1, IL-15, and IL-17A (16, 34), and this is in
keepingwith the differential expression of these cytokines dem-
onstrated in Fig. 3. Interestingly, whereas IL-6 may also be
regarded as a key regulator of inflammatory responses, it is does
not display differential peak expression in wild type andD6-de-
ficient mice, and accordingly neutralization of IL-6 had no
impact on the development of the cutaneous inflammatory
pathology in D6-deficient mice (Fig. 3D). In contrast, IL-20,
which is overexpressed in inflamed WT but not D6-deficient
mice, appears to be, at least partially, a contributor to the
inflammatory response because neutralization significantly
reduced the extent of the inflammatory response observed (Fig.
3E). Overall these data suggest differential expression of some
cytokines but that differential expression patterns do not nec-
essarily relate to the importance of cytokines for driving the
inflammatory pathology in D6-deficient mice.
Type I IFN-related Genes Represent One of the Most Signifi-
cantly Up-regulated Families of Genes—Notably, in addition to
the variable differential expression of a variety of inflammatory
cytokines, one consistency apparent from gene ranking studies
was the overexpression of genes belonging to, or regulated by,
the type I IFN pathway at day 2 in the D6-deficient mice (Table
FIGURE 3. Evidence of differential cytokine transcript levels in D6-deficient mice. Kinetics of cytokine expression, over time, within the back skin of TPA
treatedwild type (filled circles) andD6 KOmice (open circles) are indicated in the profile plots (A–C). The data are expressed as normalized intensity values (log2;
y axis) over time (days; x axis).A, profile plots indicating expression levels of IL-1, IL-6, and TNF-over the time course of the study in bothWT andD6KO skins.
None of these cytokines displayed significant differences in the magnitude of induced expression in WT and KOmice, but differences in temporal expression
were noted. *, p 0.05; **, p 0.01. B, profile plots indicating expression levels of IL-15, IL-17A, and IL-22 over the time course of the study in bothWT and KO
skins. These cytokines displayed enhanced differences in gene expression in KO mice compared with WT mice. **, p 0.01; ****, p 0.0001. C, profile plots
indicatingexpression levels of IL-1 and IL-20over the timecourseof the study inbothWTandKOskins. These cytokinesdisplayed reduceddifferences ingene
expression in KO mice compared with WT mice. **, p  0.01; ****, p  0.0001. D, KO mouse skin was either left untreated or subjected to TPA-induced
inflammation in the presence or absence of a systemically administered IL-6 neutralizing antibody. Skin thickness (epidermal plus dermal) was measured as
an indication of the extent of cutaneous inflammation. The results demonstrate no significant effect of blocking interleukin-6 on development of the cutane-
ous inflammatory pathology. n.s., not significant. E, skin thickness (epidermal plus dermal) measurements of KOmice subjected to TPA inflammation demon-
strating a significant effect of systemic anti-IL-20 administration on the development of the cutaneous inflammatory pathology.
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3). The differentially expressed type 1 IFN pathway genes
included Ifit2, Irf7, and other type I IFN-induced genes such as
Ifit44, Rsad2, Ifit2, Irf7, andMx1, which were up-regulated up
to 16-fold in D6-deficient mice, compared with WT mice
(Table 3, p 0.0001).
Hierachical Clustering and Ingenuity Pathway Analyses Con-
firm That the Type I IFN Pathway Is Significantly Up-regulated
in D6-deficient Mice—To provide further support to the
hypothesis that the type I IFNpathwaywas significantly up-reg-
ulated in D6-deficient mice at day 2, we performed hierachical
clustering of the genes differentially regulated at day 2, to iden-
tify clusters of genes that were coexpressed in these mice (sup-
plemental Fig. S4). The differentially expressed genes were
plotted over the time frame of the study for both D6-deficient
andWTmice to identify their patterns of expression.We found
that the cluster containing the 34 genes listed in Table 3 was
significantly elevated at day 2 in D6-deficientmice and was also
sustained at day 4 (supplemental Fig. S4A). Analyzing the full
list of type I IFN pathway genes using ingenuity pathway anal-
ysis demonstrated the interactive nature of the differentially
expressed components of the cluster (supplemental Fig. S4B).
In contrast, this family of genes was only up-regulated at day 4
inWTmice and in a less comprehensivemanner. This suggests,
overall, that this family of genes was expressed earlier andmore
fully in D6-deficient, compared with WT, mice. Interestingly,
these differences in expression of IFN pathway genes such as
Irf7, Ifit2, Isg15, and Stat1 were apparent (Fig. 4A, panel i),
despite there being no significant alterations in the temporal
expression patterns of either IFN or IFN (Fig. 4A, panel ii).
We also analyzed IFN and IFN protein levels in inflamed
D6-deficient mouse skin, but they were below the levels of
detection. The possible mechanisms whereby lack of altera-
tions in IFN and IFN transcript levels leads to the exagger-
ated type I IFN family gene expression in D6-deficient mice are
addressed, in more detail, under “Discussion.” A number of the
other overexpressed type I IFN pathway genes showing the
most specific elevation in D6-deficient, compared with WT,
mice are shown in the heat map in Fig. 4B. To confirm that the
IFNpathwaywas up-regulated in the skin ofD6-deficient, com-
pared withWT,mice, quantitative PCRwas performed for Irf7,
Ifit2, and CXCL9 using RNA derived from a separate skin
inflammation study (Fig. 4C). This analysis confirmed the up-
regulation of Irf7, Ifit2, and CXCL9 in the skin of D6-deficient
mice 2 days after termination of TPA treatment. There were
some differences noted in the magnitude of induction of these
three genes between the microarray and PCR analyses. How-
ever, importantly, the expression “trends” weremaintained and
confirmed in these two separate experiments. Thus, overall,
these data demonstrate the presence of an early and pro-
nounced type I IFN gene expression signature in the inflamed
skins of D6-deficient mice.
The Type I IFN Pathway Is Involved in the Development of the
Cutaneous Inflammatory Pathology in D6-deficient Skin—We
hypothesized, on the basis of the microarray data, that the
inflammation observed in the skin of D6-deficient mice was, at
least in part, dependent on the activities of type 1 IFNs within
the skin (note that IFNplays no apparent role in the pathology;
data not shown). To formally test this, neutralizing antibodies
to IFN and IFN were injected intravenously prior to and
during TPA treatment of WT and D6-deficient mice. Impor-
tantly, although antibody blockade of type I IFN activity had a
modest effect on inflammation in WT mice, as measured by
total skin thickness (supplemental Fig. 5A), this did not reach
statistical significance and was not reflected in the other mea-
sure of cutaneous inflammation, epidermal thickness (supple-
mental Fig. S5B). In contrast, we found that, after 4 days, anti-
IFN antibody treatment was associated with a significant
reduction in the inflammatory cutaneous pathology in D6-de-
ficient mice as demonstrated by decreased epidermal thickness
(Fig. 5,A andC). In addition, amodest but significant reduction
in total cutaneous T cells was observed in the anti-IFN anti-
body-treatedmice (Fig. 5,B andD). Importantly, and in keeping
with the preferential accumulation of T cells in the epidermal
compartment in inflamed D6-deficient mouse skin (16), the
difference in T cells was largely accounted for by a reduced
accumulation in the epidermal compartment (Fig. 5E). No dif-
ference in dermal T cell accumulation was noted (Fig. 5F). For
both total T cells and epidermal T cells, anti-IFN antibody
treatment reduced the levels to those seen in inflamedwild type
skin. Thus the differential expression of type I interferon
response genes reflects the importance of this pathway for
the development of the cutaneous inflammatory response in
D6-deficient mice.
TABLE 3
Differentially expressed type I IFN pathway genes in D6/ skins at
day 2
Top up-regulated genes at day 2 after TPA application in the back skin of D6-defi-
cient mice compared to wild type mice. The most highly up-regulated genes in
D6-deficient skin compared to wild type skin at day 2 after TPA application are
shown. Genes were identified using “volcano plots,” where genes significantly (p
0.05) up-regulated (fold change,3) were selected.
Probe set
identifier
Gene
symbol
Fold
change P value
1450783_at Ifit1 15.67 0.00
1421009_at Rsad2 12.88 0.00
1423555_a_at Ifit44 12.53 0.03
1418293_at Ifit2 12.35 0.00
1424339_at Oasl1 12.25 0.00
1417244_a_at Irf7 11.9 0.01
1421008_at Rsad2 11.1 0.00
1427381_at Irg1 10.73 0.04
1453196_a_at Oasl2 9.73 0.00
1436058_at Rsad2 9.45 0.00
1424775_at Oas1a 9.3 0.01
1449025_at Ifit3 8.84 0.00
1418191_at Usp18 7.74 0.00
1418930_at Cxcl10 6.37 0.00
1439114_at Ddx60 6.08 0.00
1440865_at Ifitm6 5.67 0.00
1451777_at Ddx60 5.6 0.00
1451426_at Dhx58 5.39 0.00
1425065_at Oas2 4.95 0.01
1440866_at Eif2ak2 4.05 0.00
1425374_at Oas3 3.97 0.02
1419569_a_at Isg20 3.96 0.00
1417292_at Ifi47 3.82 0.01
1452348_s_at Ifi204 3.61 0.04
1422006_at Eif2ak2 3.6 0.00
1419603_at Ifi204 3.48 0.04
1426278_at Ifi27l2a 3.46 0.00
1436562_at Ddx58 3.37 0.00
1421911_at Stat2 3.37 0.00
1419043_a_at Iigp1 3.22 0.04
1418126_at Ccl5 3.19 0.02
1424254_at Ifitm1 3.16 0.05
1450403_at Stat2 3.16 0.00
1425405_a_at Adar 3.04 0.00
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DISCUSSION
In the context of cutaneous inflammatory responses, D6-de-
ficient mice develop an exaggerated inflammatory pathology
that bears many similarities to human psoriasis (16). Further-
more, D6 is differentially expressed in psoriasis in a manner
indicative of a role in pathogenesis (34). The aim of the present
study was to define themolecular anatomy of this response and
to gain insights into the molecular basis for the impaired resolu-
tion of inflammation apparent in these mice. The data presented
demonstrate clear transcriptional differences in inflamed skins of
WT and D6-deficient mice. These differences are, in general,
indicative of accelerated and exaggerated inflammatory responses
in theD6-deficientmice.At later time points, the transcriptional
signature is indicative of alterations to epidermal differentia-
tion and remodelling, which is very much in keeping with the
histology reported in this and previous (16, 34) papers indicat-
ing massive hyperproliferation of the epidermis and aberrant
differentiation in the D6-deficient mice. The transcriptomic
patterns therefore closely reflect the pathology.
In terms of cytokine regulation of the development of the
inflammatory response in D6-deficient mice, a number of
expression patterns are observed. First, some cytokine tran-
FIGURE 4. The type I interferon pathway is overrepresented in D6 KOmice. A, panel i, profile plots demonstrating differences in the levels of induction of
type I interferon pathway genes Irf7, Ifit2, Isg15, and Stat1 in WT (filled circles) and KO (open circles) inflamed mouse skins. Panel ii, profile plots revealing the
similarity in the induced expression levels of IFN- and IFN- in WT and KO skins over the course of the induction of inflammation. In both panels i and ii, the
data are expressed as normalized intensity values (log2; y axis) over time (days; x axis). *, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001. B, heat map
analyses of the differential expression of a select group of type I interferon pathway genes over the course of the study inWT and D6-deficient (KO)mice after
TPA treatment. Black, no change; green, down-regulated; red, up-regulated. The time points are indicated along the top of the heatmap (forWT, 0 indicatesWT
day0, 1 indicatesWTday1, etc.).C, confirmatory PCRdemonstrating increasedexpressionof type I interferonpathwaygenes in inflamedD6KOcomparedwith
WT skins. Panel i, Lrf7. Panel ii, Ifit2. Panel iii, CXCL9. These PCR analyses were performed on skin samples isolated from an experiment separate from that used
to generate the array data. The data are shown as absolute copy number of each gene compared with 106 copies of -actin.
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scripts, such as IL-6, display no differences between WT and
D6-deficient mice and antibodies to IL-6 fail to ameliorate the
inflammatory pathology, indicating no active involvement of
the cytokine in the pathology. However, other cytokines dem-
onstrate either prolonged expression, as in the case of IL-1, or
enhanced expression in the case of IL-15, IL17A, and IL-22.Our
previous results indicate that IL-1, IL-15, and IL-17A, along
with TNF, are essential players in the pathology that develops
(16, 34). One important question that emerges from these
observations is why so many different cytokines can be pivotal
to the development of this inflammatory pathology. These
observations are not unusual, and numerous diverse cytokines
FIGURE 5. The pathology that develops in D6-deficient mice is dependent on the type I interferon pathway. D6-deficient (D6/) or WT mice were
injected intravenously with rabbit anti-mouse IFN- and rabbit anti-mouse IFN- or a rabbit IgG control 3 h prior to the first application of TPA (150l, 50M)
to the shaveddorsal skin. The samedoseof TPAwas applied 24h later. Thenext day, 3 hbefore the last TPAapplication, themicewere injectedwith a final dose
of rabbit anti-mouse IFN- and rabbit anti-mouse IFN-or rabbit IgG control. The inflammatory pathologywas left to develop for 4 days following the final TPA
application, after which skins were processed for histological analysis. A, H&E staining of skins at day 4 after TPA application indicating development of
inflammatory pathology in D6/ mice and the amelioration of the pathology by antibodies to type I interferons. B, CD3 T cell staining demonstrating
increased T cell recruitment into the D6/mouse skins and its suppression by antibodies to type I interferons. C, quantification of epidermal thickness at day
4 demonstrating a significant reduction in the presence of neutralizing antibodies to type I interferons.D, quantification of the number of CD3-positive T cells
in the skins atday4demonstratinga significant reduction inD6/ (KO)mice treatedwithneutralizingantibodies to type I interferons. E, specific quantification
of T cells within the epidermal compartment. F, specific quantification T cells within the dermal compartment. In C–F, each point is representative of amean of
nine separate measurements per mouse.
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have been demonstrated to play important roles in individual
murine inflammatory disease models. Perhaps the most com-
prehensive exemplar of this is collagen-induced arthritis, in
which a very broad range of cytokines has been shown to be
essential for development of the pathology (35, 36). Our inter-
pretation of this is that it suggests that pathological develop-
ment is dependent on a network of cytokines and not on indi-
vidual cytokines and that interfering with any arm of this
network is sufficient to block development of inflammatory
pathology. This therefore has implications for therapy and sug-
gests that there may be numerous distinct intervention points
in each inflammatory pathology.
One of the most striking features of our microarray data is
that it strongly highlights rapid onset and elevated expression of
transcriptional differences in genes belonging to the type I
interferon signaling pathway. In the context of D6-deficient
mice as a model of psoriasis, this is of importance because type
I interferons (produced by plasmacytoid dendritic cells) have
been clearly demonstrated to be involved in the human pathol-
ogy (37–40). Importantly, a recent microarray analysis of pso-
riatic skin in comparison to nonlesional skin has again high-
lighted the type I interferon pathway is being at play, and
therefore of therapeutic value, in human psoriasis (41). Indeed,
of the top 50 most up-regulated type I interferon-inducible
genes identified in psoriatic lesions, 25 are also up-regulated in
theD6-deficientmice, further supporting the notion that a sim-
ilar type I interferon pathway is active in this model. The ability
of antibodies to type I interferons to suppress the development
of the pathology in D6-deficient mice is therefore not entirely
surprising. However, it is interesting that this is seen despite the
fact that neither IFN or IFN display increased transcript lev-
els in D6-deficient mice. The question arises therefore how
cytokines with no enhanced transcriptional profiles can be dif-
ferentially driving pathology in wild type andD6-deficient skin.
We propose that the answer to this relates to our model of D6
function (23, 24). This model hypothesizes that the failure of
resolution of inflammation in D6-deficient mice relates to
expression of this chemokine scavenging receptor on lymphatic
endothelial cells. Specifically, in the absence of D6, inflamma-
tory chemokines congregate around the lymphatic endothelial
surfaces and trigger inappropriate association of numerous
inflammatory leukocytes with the lymphatic surface. This con-
gests the lymphatic system and impairs lymphatic drainage. A
consequence of this is that inflammatory chemokines that drive
inflammatory leukocyte recruitment, as well as the cytokines
that induce inflammatory chemokines such as TNF and the
type I IFNs, drain inefficiently from inflamed sites in D6-defi-
cient mice. This results in prolonged inflammatory cytokine
activity, and leukocyte accumulation, at such inflamed sites.
Thuswe propose that although IFN and IFN are expressed at
similar levels in wild type and D6-deficient mice, they are not
removed as efficiently from D6-deficient skin and therefore
continue to drive aspects of the pathology. In this way, we
believe, they contribute to the development of the psoriasiform
pathology. Interestingly, we have previously reported that D6
expression is increased in both keratinocytes and lymphatic
endothelial cells following exposure to type I interferons (26,
34). This suggests, therefore, that the interferon pathway not
only drives inflammation but also up-regulates D6 as feedback
to limit this response. This further explains the exaggerated
type I interferon-dependent inflammatory response in D6-de-
ficient mice.
In summary, therefore, these transcriptomic data demon-
strate strong transcriptional similarities between the D6-defi-
cientmousemodel of cutaneous inflammation and human pso-
riasis. Our data are therefore important in that they further
implicate D6 in the pathogenesis of psoriasis and provide an
essential link between reduction in D6 expression, as noted in
psoriatic plaques (26), and the development of type I IFN-
driven pro-psoriatic inflammatory responses. In addition, our
data suggest that, because D6 is transcriptionally up-regulated
by type I IFNs, this axis represents a negative feedback loop
restricting the chemokine aspect of type I IFN driven inflam-
matory responses.
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